Insulin human

Insulin — ALIMENTARY TRACT AND METABOLISM

Key facts

Insulin human is a drug in the Insulin class catalogued in DrugCentral. It was first approved by the FDA in 1982. DrugCentral lists 3 molecular targets, including Insr, LCK and INSR. Recorded indications include Diabetes mellitus type 1 and Diabetes mellitus type 2.

• Drug class: Insulin.
• Molecular targets: Insr, LCK and INSR (3 listed in DrugCentral).
• Indications: Diabetes mellitus type 1 and Diabetes mellitus type 2.
• ATC code: A10AB01 (Insulins and analogues for injection, fast-acting).
• Molecular formula: C257H383N65O77S6; molecular weight 5807.63 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Diabetes mellitus type 1
• Diabetes mellitus type 2

Off-label uses (2)

• Overdose of beta-adrenergic blocking drug
• Overdose of calcium-channel blockers

Mechanism & targets

• Established pharmacologic class: Insulin

Molecular targets (3)

Target	Gene	Action	Activity
Insulin receptor	Insr	unknown	IC50 8.71
Tyrosine-protein kinase Lck	LCK	unknown	IC50 4.74
Insulin receptor	INSR	agonist	—

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
1997-02-21	EMA	—	Sanofi-Aventis Deutschland GmbH
1982-10-28	FDA	—	LILLY

ATC classification

ATC code	Therapeutic hierarchy
A10AB01	ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › INSULINS AND ANALOGUES › Insulins and analogues for injection, fast-acting
A10AC01	ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › INSULINS AND ANALOGUES › Insulins and analogues for injection, intermediate-acting
A10AD01	ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › INSULINS AND ANALOGUES › Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
A10AE01	ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › INSULINS AND ANALOGUES › Insulins and analogues for injection, long-acting
A10AF01	ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › INSULINS AND ANALOGUES › Insulins and analogues for inhalation

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Blood glucose increased	2387.7
Hypoglycaemia	2282.9
Blood glucose decreased	871.9
Hyperglycaemia	730.7
Diabetes mellitus inadequate control	576.0
Diabetic ketoacidosis	498.8
Glycosylated haemoglobin increased	442.3
Blood glucose fluctuation	394.8
Cardiac failure congestive	252.9
Blood glucose abnormal	244.8
Anti-insulin antibody positive	227.3
Synovitis	222.2

Chemical structure

• Molecular formula: C₂₅₇H₃₈₃N₆₅O₇₇S₆
• Molecular weight: 5807.63 g/mol
• CAS number: 11061-68-0
• InChIKey: —
• PubChem CID: 118984375

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Insulin human used for?

DrugCentral lists the following indications for Insulin human: Diabetes mellitus type 1 and Diabetes mellitus type 2.

How does Insulin human work?

Its molecular targets in DrugCentral include Insr, LCK and INSR (agonist).

When was Insulin human first approved?

Insulin human was first approved by the FDA in 1982.

What drug class does Insulin human belong to?

Insulin human is in the Insulin class.

What is the chemical formula of Insulin human?

Insulin human has the molecular formula C257H383N65O77S6 and a molecular weight of 5807.63 g/mol.

Sources

• DrugCentral drug card 5003 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201540 — compound record and bioactivity
• PubChem CID 118984375 — chemical identifiers
• DrugBank DB00030 — drug record
• FDA UNII 1Y17CTI5SR — substance identity
• DailyMed: FDA labels for Insulin human — current prescribing information (label search)
• UniProt P06239 (LCK) — target protein
• UniProt P06213 (INSR) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.